- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07817017
Effect of an Early and Intensified Nutritional Intervention on the Risk of Developing Gestational Diabetes Mellitus (MedDiet in GDM)
Effect of an Early and Intensified Nutritional Intervention Based on a Mediterranean Diet (MedDiet) in Women With Clinical-genetic Risk of Developing Gestational Diabetes Mellitus (GDM): a Randomized, Parallel, Interventional, Controlled Clinical Trial
The goal of this clinical trial is to learn if a nutritional intervention based on a Mediterranean diet (MedDiet), initiated early in pregnancy, reduces the incidence of gestational diabetes mellitus (GDM) and other adverse maternal, fetal and obstetric events in pregnant women considered high-risk. It will also learn about the stratification of GDM risk based on clinical, anthropometric, analytical and genetic characteristics.
The main questions it aims to answer are:
- Does the nutritional intervention based on MedDiet reduce the incidence of GDM in women with high risk?
- How can we stratify the risk of GDM? Researchers will compare an advanced nutritional intervention based on a Mediterranean diet to standard care (general recommendations given at the beginning of pregnancy).
Participants will:
- Receive intensive nutritional counselling or standard regular recommendations during the first trimester of pregnancy.
- Visit the clinic at the time of the first ultrasound (gestational week 8-11) and at the time of screening for GDM (gestational week 24-26).
- Undergo a genetic test performed with a buccal swab.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Ana M. Ramos-Levi, MD., PhD.
- Número de teléfono: +33696938427
- Correo electrónico: ana_ramoslevi@hotmail.com
Ubicaciones de estudio
-
-
Madrid
-
Madrid, Madrid, España, 28040
- Hospital Clinico San Carlos
-
Contacto:
- Ana M. Ramos-Levi, M.D., PhD.
- Número de teléfono: +34696938427
- Correo electrónico: ana_ramoslevi@hotmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Unassisted single pregnancy;
- Age between 18 and 50 years old;
- Fasting blood glucose <92 mg/dl in the first gestational blood test;
- First trimester ultrasound before the 12th gestational week.
Exclusion Criteria:
- Multiple or assisted pregnancies;
- Any pregestational illness or pregestational treatment that may affect pregnancy;
- Known intolerance/allergy to any component of the nutritional intervention.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: Standard treatment
The nutritional intervention will consist of providing information on healthy lifestyle measures through an 8-minute informational video (accessible via QR code at the consultation room or the permanent link https://www.youtube.com/watch?v=Qgcz5t9B9WI).
Routine obstetric follow-up does not involve subsequent monitoring of adherence to these recommendations, beyond the usual follow-up.
|
|
|
Experimental: Advanced treatment
A specific nutritional intervention consisting of a group session that will last approximately one hour, led by a nutritionist from the research team.
This session will explain in detail the key aspects of the MedDiet: consumption of >40 ml/day of extra virgin olive oil, 30 g of nuts per day, 3-4 pieces of whole fruit (not juice), homemade stir-fries, 2-3 servings of vegetables and/or salads per day, 2-3 servings per day of low-fat dairy products, whole grains, 2-3 servings of legumes per week, consumption of fish, limiting the consumption of red meat, and avoiding ultra-processed products, sliced bread, soft drinks, juices, fast food, and pre-cooked products.
Two telephonic interviews will be scheduled for follow-up around gestational weeks 16 and 20 to provide motivation and assess and reinforce adherence to these recommendations.
|
The nutritional intervention consists of a 1-hour group session led by a nutritionist from the research team.
Includes a detailed description of the key aspects of the MedDiet: consumption of >40 ml/day of extra virgin olive oil, 30 g of nuts per day, 3-4 pieces of whole fruit (not juice), homemade stir-fries, 2-3 servings of vegetables and/or salads per day, 2-3 servings per day of low-fat dairy products, whole grains, 2-3 servings of legumes per week, consumption of fish, limiting the consumption of red meat, and avoiding ultra-processed products, sliced bread, soft drinks, juices, fast food, and pre-cooked products.
In addition, 2 telephonic interviews for follow-up (gestational weeks 16 and 20) to reinforce adherence and emphasize consumption of >40 ml/day of extra virgin olive oil, 30 g of nuts per day, 3-4 pieces of whole fruit (not juice), daily vegetables and daily physical activity.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of gestational diabetes mellitus
Periodo de tiempo: From enrollment (gestational week 8-11) to the time of screening for gestational diabetes mellitus (gestational week 24-26)
|
The general objective of this study is to determine whether an advanced nutritional intervention based on Mediterranean diet reduces the incidence of gestational diabetes mellitus and other adverse maternal-fetal obstetric and endocrine-metabolic events in pregnant women considered high-risk based on a risk score derived from the interaction between associated genetic polymorphisms, baseline clinical characteristics, and anthropometric characteristics of pregnant women. The primary outcome is the comparison of the frequency of GDM, according to IADPSG criteria, between the MedDiet intervention group and the standard treatment group in women at high risk according to the calculated risk of developing GDM. |
From enrollment (gestational week 8-11) to the time of screening for gestational diabetes mellitus (gestational week 24-26)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Frequency of maternal complications
Periodo de tiempo: From enrollment (gestational week 8-11) to delivery
|
Frequency of maternal complications between the MedDiet intervention group and the standard treatment group in women at high risk according to the calculated risk of developing GDM.
Variables for this outcome include: maternal weight, weight gain; risk score; frequency of maternal complications (hypertension, eclampsia, infections, carbohydrate metabolism disorders - defined as alterations in normal levels of at least one of the following: fasting glucose, HbA1c, C-peptide, insulin, HOMA-IR)
|
From enrollment (gestational week 8-11) to delivery
|
|
Frequency of fetal complications
Periodo de tiempo: From enrollment (gestational week 8-11) to delivery and neonatal period
|
Comparison of the frequency of fetal complications between the MedDiet intervention group and the standard treatment group in high-risk women, based on the calculated risk of developing gestational diabetes mellitus (GDM).
Variables for this outcome include: birth weight, hypoglycemia, potassium abnormalities, calcium abnormalities, polycythemia, admission to the neonatal intensive care unit (NICU).
|
From enrollment (gestational week 8-11) to delivery and neonatal period
|
|
Frequency of obstetric complications
Periodo de tiempo: From enrollment (gestational week 8-11) to delivery and immediate postpartum
|
Comparison of the frequency of obstetric complications between the MedDiet intervention group and the standard treatment group in women at high risk of developing GDM.
Variables for this outcome include: type of delivery, dystocia, lacerations during delivery, preterm or postterm delivery (gestational week at delivery).
|
From enrollment (gestational week 8-11) to delivery and immediate postpartum
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades del sistema endocrino
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades metabólicas
- Complicaciones del embarazo
- Trastornos del metabolismo de la glucosa
- Diabetes mellitus
- Enfermedades Nutricionales y Metabólicas
- Diabetes Gestacional
Otros números de identificación del estudio
- PI25_01413
- 25/902-EC_X (Otro identificador: Ethics Committee of the Hospital Clinico San Carlos)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The original protocols of the study will be stored in a locked office in the Department of Endocrinology at our Hospital. De-identified data will be saved on a secure electronic database. Specifically, we will use REDCap® (Vanderbilt University) software, which is known to be a secure, browser-based web application (http://project-redcap.org), for data entry and analysis.
All participant data related to the study, including scales and questionnaires, will be completed in paper form, and will then be recorded and uploaded in the REDCap®Electronic Data Collection Record (eCRD).
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .